<DOC>
	<DOCNO>NCT01712945</DOCNO>
	<brief_summary>The purpose study test novel strategy prevent clinical problem secondary autoimmunity follow alemtuzumab treatment multiple sclerosis . The hypothesis autoimmunity alemtuzumab prevent give drug promotes thymic T cell regeneration ( Palifermin , Kepivance® ) .</brief_summary>
	<brief_title>Keratinocyte Growth Factor Prevent Autoimmunity After Alemtuzumab Treatment Multiple Sclerosis</brief_title>
	<detailed_description>This single-centre , double-blinded , randomise control trial palifermin ( Kepivance ) vs. placebo prevention autoimmunity follow alemtuzumab treatment multiple sclerosis . The dose palifermin ( kepivance ) use trial inform dose-escalation study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Male nonpregnant , nonlactating female patient &gt; 18 year age , &lt; 50 year age inclusive Diagnosis MS use McDonald 's 2010 criterion , include MRI abnormality consistent McDonald 's 2010 criterion . Onset first MS symptom within 10 year date ICF sign EDSS score 0.0 5.0 ( inclusive ) screen At least 2 clinical episode MS 2 year prior study entry , least 1 attack within 12 month , may occur whilst diseasemodifying therapy , namely beta interferon glatiramer acetate . Serum IL7≤7pg/mL Any progressive form multiple sclerosis Previous thymectomy Previous treatment alemtuzumab , natalizumab , mitoxantrone , cyclophosphomide , cladribine , rituximab immunosuppressant cytotoxic therapy ( steroid diseasemodifying therapy list ) History malignancy Personal history clinically significant autoimmune disease , multiple sclerosis ( include limit : thyroid disease , immune cytopenia , inflammatory bowel disease , diabetes , lupus , severe asthma ) Intolerance pulse corticosteroid , especially history steroid psychosis Major systemic disease illness would , opinion investigator , compromise patient safety interfere interpretation study result . Seropositivity human immunodeficiency virus ( HIV ) Past present hepatitis B infection ( positive hepatitis B serology ) Pregnant woman male female patient agree use effective contraception study . Medical , psychiatric , cognitive condition , investigator 's opinion , compromise patient 's ability understand patient information , give informed consent , comply trial protocol , complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Reconstitution</keyword>
	<keyword>Thymus</keyword>
</DOC>